Immunovant, Inc. IMVT Business Segments — Interest Income (Expense), Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s business segments — interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s business segments — interest income (expense), nonoperating?
- Immunovant, Inc. (IMVT) reported business segments — interest income (expense), nonoperating of $8.06M in Q1 2026.
- How has Immunovant, Inc.'s business segments — interest income (expense), nonoperating changed year-over-year?
- Immunovant, Inc.'s business segments — interest income (expense), nonoperating increased by 17.0% year-over-year, from $6.89M to $8.06M.
- What is the long-term trend for Immunovant, Inc.'s business segments — interest income (expense), nonoperating?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s business segments — interest income (expense), nonoperating has grown at a 49.5% compound annual growth rate (CAGR), from $7.58M to $25.33M.
- What does business segments — interest income (expense), nonoperating mean?
- Represents the net impact of interest income earned on cash balances and interest expenses incurred on debt obligations for the segment. This metric highlights the non-operating financial performance and the company's ability to generate returns on its capital reserves. It provides insight into the segment's liquidity position and financial management efficiency.